The Study of MDM2 rs937283 Variant and Cancer Susceptibility in a Central Chinese Population

Bifeng Chen, PhD1, Jingdong Wang, MSc1, Jieling Wang, MSc1, Jingli Zhang, PhD1, Xiuli Gu, MM2,3, and Xianhong Feng, MM4

Abstract
The rs937283 variant, locating in murine double minute 2 promoter region, has been previously reported to potentially alter the promoter activity and to influence cancer susceptibility. In this study, we investigated the association of murine double minute 2 rs937283 variant and cancer susceptibility in a central Chinese population, followed by a meta-analysis. A total of 1058 healthy controls, 480 patients with breast cancer, 384 patients with cervical cancer, 480 patients with liver cancer, 426 patients with colon cancer, and 361 patients with rectal cancer were recruited in this case–control study. The murine double minute 2 rs937283 was genotyped by polymerase chain reaction restriction fragment length polymorphism and confirmed by sequencing. Our case–control analysis revealed that rs937283 was associated with the susceptibility to breast and liver cancer, but not cervical, colon, or rectal cancer. Specifically, the G allele of rs937283 conferred a significantly increased risk of breast and liver cancer. Moreover, results of meta-analysis demonstrated that rs937283 was significantly associated with cancer susceptibility, and this significant association remained in Asian (Chinese) population, but not in Caucasian population. Collectively, the murine double minute 2 rs937283 variant may serve as a potential biomarker for cancer predisposition in Chinese population.

Keywords
MDM2, rs937283, genetic variation, cancer susceptibility, meta-analysis

Abbreviations
CI, confidence interval; DTC, differentiated thyroid carcinoma; ESCC, esophageal squamous cell carcinoma; HWE, Hardy-Weinberg equilibrium; LaC, laryngeal carcinoma; LuC, lung cancer; MDM2, murine double minute 2; mRNA, messenger RNA; OR, odds ratio; OSCC, oral squamous cell carcinoma; PCR, polymerase chain reaction; RB, retinoblastoma; SCCHN, squamous cell carcinoma of the head and neck; SGC, salivary gland carcinoma.

Introduction
The murine double minute 2 (MDM2) gene, encoding an apoptosis inhibiting protein, has been shown to play a pivotal role in a variety of physiological and pathological processes.1 Moreover, elevated expression of MDM2 occurs in diverse human cancers and is linked to carcinogenesis or malignant transformation.2 The underlying mechanism may be attributed to the fact that the MDM2 protein forms a complex with the TP53 protein, attenuates the activity of TP53, and promotes the subsequent degradation of TP53 by acting as an ubiquitin E3 ligase for TP53.3 Thus, MDM2 is regarded as a modifier gene in cancer development.

Human cancers have been the serious diseases affecting human health and life. Because of various carcinogenic factors and accumulated exposure to carcinogenic conditions, the...
incidences of human cancers have increased year by year during the past decade in China. The current knowledge suggests that occurrence of human tumor is the result of accumulation of genetic and epigenetic changes in genome. The association of genetic factors (especially genetic variants) and human cancers has attracted a lot of attention. Accumulating evidence supports the correlation between the alteration in protein structural/functional behavior/abnormal expression and genetic variants within relative genes. Interestingly, the rs937283 is such a genetic variant that significantly enhances the transcription activity of the MDM2 gene and thereby increases the messenger RNA (mRNA) and protein expression levels of MDM2. Until now, there has been no report investigating the association of this genetic variant with susceptibility to breast cancer, cervical cancer, liver cancer, colon cancer, or rectal cancer. To determine the role of MDM2 rs937283 variant in these cancers, we in this study analyzed the distribution of rs937283 and assessed the association of MDM2 with susceptibility to breast cancer, cervical cancer, liver cancer, colon cancer, and rectal cancer in a central Chinese population.

Several studies have investigated the association between rs937283 and susceptibility to multiple cancers. However, the results remain conflicting rather than conclusive. To solve the discrepancies and the problem of inadequate statistical strength among previous studies, we further performed a meta-analysis, integrating the data from previous literatures and our present study, to get a more precise and reliable assessment of the association between MDM2 rs937283 variant and cancer susceptibility.

Materials and Methods

Participants

A total of 1058 healthy controls (558 males and 500 females), 480 patients with breast cancer, 384 patients with cervical cancer, 480 patients with liver cancer, 426 patients with colon cancer, and 361 patients with rectal cancer were enrolled in this study. The patients with cancer were confirmed histopathologically and volunteers were recruited from Hubei Cancer Hospital and Wuhan Xinzhou District People’s Hospital between January 2015 and December 2016. The healthy controls were selected from cancer-free individuals who visited Wuhan Xinzhou District People’s Hospital for regular physical examinations between September 2014 and December 2016 or who volunteered to participate in the epidemiology survey during the same period. Importantly, the controls were frequency matched to the cases by age (±5 years), gender, smoking status, and drinking status. The response rate of the eligible controls was approximately 85%. All participants were biologically unrelated Han Chinese living in central China (Hubei province). This study was approved by the ethical committees of Wuhan University of Technology and written informed consent for the genetics analysis was obtained from all participants or their guardians.

The Genotyping of MDM2 rs937283 Variant

The peripheral blood samples (5 mL per participant) were collected into blood vacuum tubes containing EDTA and stored at 4°C. Genomic DNA was extracted from blood samples using the TIANamp Blood DNA Kit (DP348; TianGen Biotech, Beijing, China), according to the manufacturer’s instructions, and stored at −20°C before use. The A to G substitution at rs937283 creates an AvaiII restriction site; thus, genotyping of MDM2 rs937283 variant was subsequently performed via polymerase chain reaction (PCR) restriction fragment length polymorphism technique. Briefly, a 175 bp DNA fragment containing the polymorphism of interest was amplified with the primers (forward: 5'-GGGACCCCCCTCGGACGA-3' and reverse: 5'-CCTCAAGACTCCCCAGTATTC-3'). The PCR products were then digested with 10-unit AvaII restriction enzymes following the manufacturer’s instructions (Takara, Bio Inc, Shiga, Japan). Digested fragments were separated by electrophoresis on 3% agarose gel and visualized under ultraviolet light with GelRed staining. The rs937283 G allele was identified by the presence of 2 bands (107 and 68 bp), whereas the A allele was identified by the presence of 1 band (175 bp). Genotyping analysis was repeated twice for all participants, and the results were 100% concordant. Next, 20% randomly selected PCR-amplified DNA samples were examined by DNA sequencing, and the results were also 100% concordant.

Statistical Analysis

All statistical analyses were performed with the Statistical Program for Social Sciences (SPSS, version 15.0, Chicago, Illinois). Two-sided $\chi^2$ test was used to compare the differences in age, gender, smoking status, and alcohol status between patients with cancer and healthy controls. Genotypic frequency of rs937283 in healthy controls was tested for departure from Hardy-Weinberg equilibrium (HWE). Logistic regression analysis was used to estimate the association between rs937283 and cancer susceptibility. $P < .05$ was considered as statistically significant, and the Bonferroni correction for multiple testing was applied.

Meta-Analysis

A comprehensive literature search updated to April of 2018 was carried out in PubMed, EMBASE, ISI Web of Science, and CNKI and Wanfang databases without language restriction. The search terms used were as follows: mouse double minute 2 homolog, proto-oncogene proteins c-mdm2, MDM2, MDM2 proto-oncogene, E3 ubiquitin protein ligase, human homolog of mouse double minute 2, murine double minute 2 homolog, proto-oncogene proteins c-mdm2, MDM2, MDM2 proto-oncogene, E3 ubiquitin protein ligase, human homolog of mouse double minute 2, murine double minute 2, polymorphism, variant, mutation, SNP, single nucleotide polymorphism, rs937283, cancer, tumor, carcinoma. References listed in retrieved articles were also checked for missing information. Next, studies were eligible for inclusion in the meta-analysis if they met the following criteria: (1) studies on humans, (2) investigation of the MDM2 rs937283 variant and
Table 1. Demographic Characteristics of Patients With Breast Cancer, Patients With Cervical Cancer, and Healthy Females.

| Variable          | Patients With Breast Cancer (n = 480) | Patients With Cervical Cancer (n = 384) | Healthy Females (n = 500) | P Valuea |
|-------------------|--------------------------------------|----------------------------------------|---------------------------|----------|
| Age               | ≤60 years 274 (57.1%)b                | 204 (53.1%)                            | 292 (58.4%)               | .677     |
|                   | >60 years 206 (42.9%)                 | 180 (46.9%)                            | 208 (41.6%)               | .117     |
| Smoking status    | Ever 137 (28.5%)                     | 112 (29.2%)                            | 137 (27.4%)               | .691     |
|                   | Never 343 (71.5%)                    | 272 (70.8%)                            | 363 (72.6%)               | .563     |
| Drinking status   | Ever 143 (29.8%)                     | 116 (30.2%)                            | 141 (28.2%)               | .583     |
|                   | Never 337 (70.2%)                    | 268 (69.8%)                            | 359 (71.8%)               | .515     |

aTwo-sided χ² test for the distributions of age, smoking status, and drinking status between patients with breast cancer and healthy females (left column), as well as between patients with cervical cancer and healthy females (right column).

Table 2. Demographic Characteristics of Patients With Liver Cancer, Patients With Colorectal Cancer, and Healthy Controls.

| Variables          | Patients With Liver Cancer (n = 480) | Patients With Colon Cancer (n = 426) | Patients With Rectal Cancer (n = 361) | Healthy Controls (n = 800) | P Valuea |
|--------------------|--------------------------------------|--------------------------------------|---------------------------------------|---------------------------|----------|
| Age                | ≤60 years 280 (58.3%)b                | 245 (57.5%)                          | 210 (58.2%)                          | 434 (54.3%)               | .154     |
|                   | >60 years 200 (41.7%)                 | 181 (42.5%)                          | 151 (41.8%)                          | 366 (45.7%)               | .274     |
| Gender             | Male 343 (71.5%)                     | 309 (72.5%)                          | 246 (68.1%)                          | 558 (69.7%)               | .213     |
|                   | Female 137 (28.5%)                   | 117 (27.5%)                          | 115 (31.9%)                          | 242 (30.3%)               | .583     |
| Smoking status     | Ever 140 (29.2%)                     | 128 (30.0%)                          | 100 (27.7%)                          | 209 (26.1%)               | .574     |
|                   | Never 340 (70.8%)                    | 298 (70.0%)                          | 261 (72.3%)                          | 591 (73.9%)               | .143     |
| Drinking status    | Ever 158 (32.9%)                     | 135 (31.7%)                          | 122 (33.8%)                          | 237 (29.6%)               | .155     |
|                   | Never 322 (67.1%)                    | 291 (68.3%)                          | 239 (66.2%)                          | 563 (70.4%)               |          |

aTwo-sided χ² test for the distributions of age, smoking status, and drinking status between patients with liver cancer and healthy controls (left column), between patients with colon cancer and healthy controls (middle column), as well as between patients with rectal cancer and healthy controls (right column).

Results

The demographic characteristics of patients with cancer and healthy controls are presented in Tables 1 and 2. There were no significant differences in the distributions between patients with cancer and healthy controls relating to age, gender, smoking status, and drinking status. These results suggested that patients with cancer and healthy controls were well matched in the present case–control study.

Five types of patients with cancer (breast cancer, cervical cancer, liver cancer, colon cancer, and rectal cancer) were included in this study, and the MDM2 rs937283 variant was successfully genotyped in a total of 3189 participants. Table 3 showed us the allele/genotype distributions of rs937283 and their association with cancer susceptibility. The genotype frequencies of rs937283 among controls were in accordance with HWE (P = .871 and .344, respectively), indicating that the included control participants were representative. No significant association was identified for rs937283 with the susceptibility to cervical cancer, colon cancer, rectal cancer, or combined colorectal cancer. In contrast, rs937283 was shown to significantly associate with the susceptibility to breast and liver cancers. The allele/genotype distributions of rs937283 were significantly different between patients with breast cancer and healthy females (P = .003 and .008, respectively), as well as between patients with liver cancer and healthy controls (P = .001 and .004, respectively). Furthermore, logistic regression analysis was applied to estimate the association of rs937283 with susceptibility to breast and liver cancer. After Bonferroni correction for multiple testing (0.05/5 = 0.01), it was still found that the G allele and GG genotype of rs937283 were associated with an increased susceptibility to breast cancer than the A allele and AG/AA genotypes, respectively (G vs A, GG vs AA, and GG vs AG + AA). Similarly, the G allele and G variant genotypes of rs937283 significantly
increased the susceptibility to liver cancer (G vs A, GG vs AA, GG vs AG + AA, and GG + AG vs AA).

According to the inclusion criteria, we finally retrieved 9 relevant literatures. The characteristics of included studies in this meta-analysis are summarized in Table 4. The genotype frequencies of rs937283 among controls were in accordance with HWE in each study (P > .05). Of note, the adjusted P value (<.01, .05/5) using Bonferroni correction was also applied. As shown in Table 5, the meta-analysis revealed a significant association between rs937283 and cancer susceptibility in 2 genetic models (G vs A, odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.06-1.30, P = .003; GG + AG vs AA, OR = 1.21, 95% CI = 1.06-1.38, P = .004). In the further ethnicity-stratified analysis, no association was found for rs937283 with cancer susceptibility in Caucasian population, whereas rs937283 was significantly associated with cancer susceptibility in Asian population in 3 genetic models (G vs A, OR = 1.30, 95% CI = 1.13-1.49, P < .001; AG vs AA, OR = 1.26, 95% CI = 1.13-1.41, P < .001; GG + AG vs AA, OR = 1.30, 95% CI = 1.17-1.44, P < 0.001). In addition, the results of Begg test and Egger test demonstrated that the occurrence of publication bias was excluded under all genetic models (Table 5, all P > .05), suggesting that our statistical results were credible.

### Discussion

Cancer has been a global health problem and a threat to human health and development. Among both men and women, the majority of deaths worldwide are due to cancers. Liver cancer, colorectal cancer (colon and rectal cancers), and 2 female-specific cancers (breast and cervical cancer) are the most common cancer types and cause lots of cancer-related deaths in China. Despite tremendous progress in the treatment of human cancers in recent decades, the prognosis remains unsatisfactory, especially in advanced stage tumors with distant metastasis. Therefore, identification of the inherited variants associated with cancer susceptibility would be useful in making early diagnosis and risk prediction.

---

**Table 3. Genotype and Allele Distributions of MDM2 rs937283 Variant and Its Association With Cancer Susceptibility.**

| Group       | rs937283 | Cases   | Controls | P Valuea | Logistic Regression, P Value, OR (95% CI)b | HWE Testc |
|-------------|----------|---------|----------|----------|---------------------------------------------|-----------|
| Breast cancer | A        | 759 (79.1%d | 842 (84.2%) | .003    | G vs A .003, 1.41 (1.12-1.78)                |           |
|             | G        | 201 (20.9%) | 158 (15.8%) | .008    | GG vs AA .005, 2.70 (1.34-5.38)              | 0.871     |
|             | AA       | 307 (64.0%) | 354 (70.8%) | .022    | AG vs AA .122, 1.25 (0.95-1.64)              |           |
|             | AG       | 145 (30.2%) | 134 (26.8%) | .022    | GG + AG vs AA .022, 1.36 (1.03-1.80)         |           |
|             | GG       | 28 (5.8%)   | 12 (2.4%)  | .009    | GG vs AG + AA .009, 2.50 (1.27-5.00)         |           |
| Cervical cancer | A        | 630 (82.0%) | 842 (84.2%) | .226    | G vs A .226, 1.17 (0.91-1.50)                |           |
|             | G        | 138 (18.0%) | 158 (15.8%) | .417    | GG vs AA .745, 1.13 (0.50-2.70)              | 0.871     |
|             | AA       | 256 (66.7%) | 354 (70.8%) | .191    | AG vs AA .191, 1.20 (0.93-1.60)              |           |
|             | AG       | 118 (30.7%) | 134 (26.8%) | .188    | GG + AG vs AA .188, 1.19 (0.90-1.65)         |           |
|             | GG       | 10 (2.6%)   | 12 (2.4%)  | .847    | GG vs AG + AA .847, 1.10 (0.46-2.50)         |           |
| Liver cancer | A        | 783 (81.6%) | 1382 (86.4%) | .001   | G vs A .001, 1.43 (1.15-1.78)                |           |
|             | G        | 177 (18.4%) | 218 (13.6%) | .005    | GG vs AA .005, 2.44 (1.30-4.56)              |           |
|             | AA       | 327 (68.1%) | 600 (75.0%) | .050    | AG vs AA .050, 1.30 (1.00-1.66)              | 0.344     |
|             | AG       | 129 (26.9%) | 182 (22.8%) | .078    | GG + AG vs AA .078, 1.38 (1.10-1.78)         |           |
|             | GG       | 24 (5.0%)   | 18 (2.2%)  | .009    | GG vs AG + AA .009, 2.29 (1.20-4.25)         |           |
| Colon cancer | A        | 720 (84.5%) | 1382 (86.4%) | .208  | G vs A .208, 1.16 (0.92-1.47)                |           |
|             | G        | 132 (15.5%) | 218 (13.6%) | .818    | GG vs AA .818, 1.09 (0.51-2.40)              |           |
|             | AA       | 304 (71.4%) | 600 (75.0%) | .163    | AG vs AA .163, 1.21 (0.90-1.58)              | 0.344     |
|             | AG       | 112 (26.3%) | 182 (22.8%) | .168    | GG + AG vs AA .168, 1.19 (0.92-1.55)         |           |
|             | GG       | 10 (2.3%)   | 18 (2.2%)  | .913    | GG vs AG + AA .913, 1.02 (0.45-2.80)         |           |
| Rectal cancer | A        | 605 (83.8%) | 1382 (86.4%) | .101  | G vs A .101, 1.23 (0.96-1.57)                |           |
|             | G        | 117 (16.2%) | 218 (13.6%) | .681    | GG vs AA .681, 1.17 (0.53-2.65)              |           |
|             | AA       | 253 (70.1%) | 600 (75.0%) | .808    | AG vs AA .808, 1.28 (0.96-1.70)              | 0.344     |
|             | AG       | 99 (27.4%)  | 182 (22.8%) | .079    | GG + AG vs AA .079, 1.26 (0.95-1.69)         |           |
|             | GG       | 9 (2.5%)    | 18 (2.2%)  | .799    | GG vs AG + AA .799, 1.09 (0.50-2.49)         |           |
| Colorectal cancer | A        | 1325 (84.2%) | 1382 (86.4%) | .081  | G vs A .081, 1.19 (0.98-1.45)                |           |
|             | G        | 249 (15.8%) | 218 (13.6%) | .701    | GG vs AA .701, 1.15 (0.60-2.20)              |           |
|             | AA       | 557 (70.8%) | 600 (75.0%) | .058    | AG vs AA .058, 1.24 (1.00-1.55)              | 0.344     |
|             | AG       | 211 (26.8%) | 182 (22.8%) | .059    | GG + AG vs AA .059, 1.20 (0.99-1.53)         |           |
|             | GG       | 19 (2.4%)   | 18 (2.2%)  | .828    | GG vs AG + AA .828, 1.05 (0.50-2.05)         |           |

Abbreviations: CI, confidence interval; HWE, Hardy-Weinberg equilibrium; OR, odds ratio.

aAllele/genotype frequencies in cases and controls were compared using 2-sided χ² test.

bOR (95% CI) was estimated by logistic regression analysis and adjusted for age, sex, smoking status, and alcohol use.

cGenotypic frequency of rs937283 in controls was tested for departure from HWE using 2-sided χ² test.

dNumbers in parentheses, percentage.
Increasing evidence has indicated that MDM2-TP53 pathway plays an important role in tumor development and progression. The dysregulation of MDM2 would impair the MDM2-TP53 pathway and thereby might affect individual susceptibility to cancer. The rs937283 variant was a novel functional variant identified in MDM2 gene promoter. Jiao et al. proved that the transition of A to G at rs937283 significantly enhanced the transcription activity of the MDM2 gene in vitro.

Table 4. Characteristics of the Present and Previous Studies.

| References (Author, Year) | Ethnicity | Cancer Type | Genotyping Assay | Case, Control (n) | HWE Test |
|---------------------------|-----------|-------------|------------------|------------------|----------|
| Li et al8                 | Caucasian | Lung cancer | PCR-RFLP         | 1026, 1145       | 844/1208, 935/1355 | 175/494/357, 181/573/391 | 0.227 |
| Chen et al15              | Caucasian | Oral squamous cell carcinoma | PCR-RFLP | 325, 335 | 303/347, 273/397 | 47/209/69, 52/169/114 | 0.715 |
| Jin et al9                | Caucasian | Salivary gland carcinoma | PCR-RFLP | 156, 511 | 126/186, 421/601 | 29/68/59, 83/255/173 | 0.795 |
| de Oliveira Reis et al10  | Caucasian | Retinoblastoma | PCR-RFLP | 104, 104 | 83/125, 70/138 | 16/51/37, 11/48/45 | 0.943 |
| Yu et al11               | Caucasian | Squamous cell carcinoma of the head and neck | TaqMan assay | 1078, 1145 | 896/1260, 939/1239 | 187/522/369, 205/529/355 | 0.749 |
| Zhang et al12            | Caucasian | Differentiated thyroid carcinoma | PCR-RFLP | 303, 511 | 251/355, 427/595 | 52/147/104, 89/249/173 | 0.971 |
| Yang et al13             | Asian     | Esophageal squamous cell carcinoma | TaqMan assay | 426, 511 | 126/186, 421/601 | 29/68/59, 83/255/173 | 0.943 |
| Jiao et al7              | Asian     | Breast cancer | TaqMan assay | 361, 800 | 177/783, 218/1382 | 24/129/327, 18/182/600 | 0.344 |
| This study               | Asian     | Cervical cancer | PCR-RFLP | 426, 800 | 177/783, 218/1382 | 24/129/327, 18/182/600 | 0.344 |
| This study               | Asian     | Laryngeal carcinoma | PCR-RFLP | 480, 500 | 201/759, 158/842 | 28/145/720, 12/134/354 | 0.871 |

Abbreviations: HWE, Hardy-Weinberg equilibrium; PCR-RFLP, polymerase chain reaction restriction fragment length polymorphism.

Table 5. Meta-Analysis of the Association Between MDM2 rs937283 Variant and Cancer Susceptibility.

| Genetic Model | Heterogeneity Test | Summary OR (95% CI) | Hypothesis Test | Begg Test | Egger Test | Studies |
|---------------|--------------------|----------------------|-----------------|-----------|-----------|---------|
| rs937283 and cancer susceptibility |                |                     |                 |           |           |         |
| G vs A        | 0.79 < 1 x 10^-3   | 1.17 (1.06-1.30)    | 3.00 < 0.003    | 1.16 < 0.246 | 1.75 < 0.222 | 14      |
| GG vs AA      | 55% 1.30 (1.04-1.62)| 2.34 < 0.019        | 1.77 < 0.177    | 2.15 < 0.054 | 10 < 14    | 14      |
| AG vs AA      | 57% 1.14 (1.04-1.34)| 2.55 < 0.011        | 0.55 < 0.583    | 1.68 < 0.134 | 10 < 14    | 14      |
| GG + AG vs AA | 64% 1.10 (1.06-1.34)| 2.84 < 0.004        | 0.43 < 0.669    | 2.03 < 0.067 | 10 < 14    | 14      |
| GG vs AG + AA | 43% 1.18 (0.99-1.42)| 1.82 < 0.069        | 1.65 < 0.100    | 2.05 < 0.064 | 10 < 14    | 14      |

Abbreviations: CI, confidence interval; OR, odds ratio.

Increasing evidence has indicated that MDM2-TP53 pathway plays an important role in tumor development and progression. The dysregulation of MDM2 would impair the MDM2-TP53 pathway and thereby might affect individual susceptibility to cancer. The rs937283 variant was a novel functional variant identified in MDM2 gene promoter. Jiao et al. proved that the transition of A to G at rs937283 significantly enhanced the transcription activity of the MDM2 gene in vitro.
Therefore, rs937283 variant was a potential risk factor for cancer susceptibility. Indeed, we here identified that MDM2 rs937283 variant significantly increased the susceptibility to breast and liver cancer in a central Chinese population. However, inconsistent results were observed when exploring the association between rs937283 and susceptibility to cervical and colorectal cancer. So far, 9 studies have been investigated the association between rs937283 and cancer susceptibility, including lung cancer (LuC), oral squamous cell carcinoma (OSCC), salivary gland carcinoma (SGC), retinoblastoma (RB), squamous cell carcinoma of the head and neck (SCCHN), differentiated thyroid carcinoma (DTC), esophageal squamous cell carcinoma (ESCC), and laryngeal carcinoma (LaC). Similarly, the results remain conflicting rather than conclusive. Specifically, MDM2 rs937283 was shown to be associated with the susceptibility to OSCC, LaC, and RB (in Asian), but not to LuC, SGC, SCCHN, DTC, ESCC, or RB (in Caucasian). One possibility for these discrepancies may be attributed to the different cancer types. The regulation of MDM2 expression is complex in normal cells, and the regulation of rs937283 variant on MDM2 expression may vary from cell types. Admittedly, different environments, lifestyles, and genetic backgrounds among different ethnic populations and small sample size may also contribute to the differences in the association of rs937283 and susceptibility to different types of cancers.

Currently, the meta-analysis is a statistical tool for combining the results from different studies on the same topic to increase the statistical strength and precision in estimating effects. Therefore, a meta-analysis was further performed to estimate the real effect of rs937283 on cancer susceptibility. Interestingly, we found a positive association between rs937283 variant and increased cancer susceptibility in the overall population and Asian population. The explanation for this observation may be that the G allele of rs937283 variant in the MDM2 promoter region is closely linked to the high expression levels of MDM2 mRNA and protein, which enhances the degradation of TP53 and thereby increases the cancer susceptibility. However, no significant association between rs937283 variant and cancer susceptibility was present in the Caucasian-stratified analysis, suggesting differences in genetic background may be a possible reflection of rs937283 on cancer susceptibility. Therefore, larger studies performed in different ethnicities are warranted to validate or further reinforce our present findings.

Genetic testing can identify individuals with an increased risk for human diseases such as cancer. The present findings in liver and breast cancer may be applied in clinical practice. Early identification of at-risk patients with liver/breast cancer may slow the progression of the disease through individualized treatment. Additionally, environmental risk factors can be identified and lifestyle modifications can be made to reduce the risk for developing liver/breast cancer. However, it should be noted that our study contained several limitations. First, we used a hospital-based case–control study design. Therefore, the potential for selection bias should be considered. Second, it cannot rule out the possibility that the MDM2 rs937283 variant may not be the causal loci but rather be in linkage disequilibrium with the causal loci. Third, the effect of rs937283 variant on MDM2 expression was not assessed in liver/breast cancer tissues from individuals with different rs937283 genotypes, which should be analyzed in further confirmatory study. Fourth, the underlying molecular mechanism for the regulation of rs937283 on MDM2 transcription activity remains unclear, which needs to be addressed in future functional studies. Finally, our current observations only involved Han Chinese population; thus, further confirmatory studies are demanded in other ethnic groups.

Conclusion

Our study provided statistical evidence that MDM2 rs937283 variant significantly increases the susceptibility to breast and liver cancer, but not cervical cancer, colon cancer, or rectal cancer in a central Chinese population. We further demonstrated that MDM2 rs937283 variant is more likely to confer an increased genetic susceptibility to cancer susceptibility in Asian (Chinese) population, but not in Caucasian population. MDM2 rs937283 variant may serve as a valuable risk factor or diagnostic biomarker among Chinese patients with cancer and needs more supporting evidence.

Authors’ Note

This study was approved by the Ethical Committees of Wuhan University of Technology (approval no: WUT02720171123), and written informed consent for the genetics analysis was obtained from all participants or their guardians. Bifeng Chen and Jingdong Wang contributed equally to this work.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the National Natural Science Foundation of China (81502427) and the Fundamental Research Funds for the Central Universities (WUT: 2018IB021 and 2018IB023).

ORCID iD

Bifeng Chen, PhD http://orcid.org/0000-0001-5482-1910

References

1. Mendoza M, Mandani G, Momand J. The MDM2 gene family. Biomol Concepts. 2014;5(1):9-19.
2. Shaikh MF, Morano WF, Lee J, et al. Emerging role of MDM2 as target for anti-cancer therapy: a review. Ann Clin Lab Sci. 2016;46(6):627-634.
3. Wei J, Yang Y, Lu M, et al. Escape, or vanish: control the fate of p53 through MDM2-mediated ubiquitination. Anticancer Agents Med Chem. 2015;16(2):174-189.
4. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin*. 2016;66(2):115-132.
5. Herceg Z, Vaissiere T. Epigenetic mechanisms and cancer: an interface between the environment and the genome. *Epigenetics*. 2011;6(7):804-819.
6. Shastry BS. SNPs: impact on gene function and phenotype. *Methods Mol Biol*. 2009;578:3-22.
7. Jiao Y, Jiang Z, Wu Y, Chen X, Xiao X, Yu H. A functional polymorphism (rs937283) in the MDM2 promoter region is associated with poor prognosis of retinoblastoma in Chinese han population. *Sci Rep*. 2016;6:31240.
8. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. *Carcinogenesis*. 2006;27(10):2028-2033.
9. Jin L, Xu L, Song X, Wei Q, Sturgis EM, Li G. Genetic variation in MDM2 and p14ARF and susceptibility to salivary gland carcinoma. *PLoS One*. 2012;7(11):e49361.
10. de Oliveira Reis AH, de Carvalho IN, et al. Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. *Pediatr Blood Cancer*. 2012;59(1):39-43.
11. Yu H, Huang YJ, Liu Z, et al. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. *Mol Carcinog*. 2011;50(9):697-706.
12. Zhang F, Xu L, Wei Q, Song X, Sturgis EM, Li G. Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. *Surgery*. 2013;153(5):711-717.
13. Yang J, Liu B, Li W, et al. Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC). *Cancer Epidemiol*. 2013;37(5):629-633.
14. Wang H, Ma K. Association between MDM2 rs769412 and rs937283 polymorphisms with alcohol drinking and laryngeal carcinoma risk. *Int J Clin Exp Pathol*. 2015;8(6):7436-7440.
15. Chen X, Sturgis EM, Lei D, Dahlstrom K, Wei Q, Li G. Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. *Cancer Res*. 2010;70(18):7199-7208.
16. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Ann Intern Med*. 1997;127(9):820-826.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst*. 1959;22(4):719-748.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.
19. Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. *Br Med Bull*. 2009;92:7-32.
20. Masters GA, Krilov L, Bailey HH, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol*. 2015;33(7):786-809.
21. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nat Rev Cancer*. 2013;13(2):83-96.
22. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell*. 1992;69(7):1237-1245.
23. Lee YH. Meta-analysis of genetic association studies. *Ann Lab Med*. 2015;35(3):283-287.